FGFR2 and cholangiocarcinoma: In a phase II study of BGJ398 in 61 patients with FGFR‐altered advanced cholangiocarcinoma, the overall response rate was 14.8% (18.8% FGFR2 fusions only), disease control rate was 75.4% (83.3% FGFR2 fusions only), and estimated median progression‐free survival was 5.8 months (95% CI, 4.3‐7.6 months).51